Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 2/20 | 0.46 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.46 |
| ▸ | CNR2 | P34972 | 2/20 | 0.46 |
| ▸ | TUBB4A | P04350 | 11/20 | 0.46 |
| ▸ | TUBB | P07437 | 11/20 | 0.46 |
| ▸ | TUBA3C | P0DPH7 | 11/20 | 0.46 |
| ▸ | TUBA1B | P68363 | 11/20 | 0.46 |
| ▸ | TUBA4A | P68366 | 11/20 | 0.46 |
| ▸ | TUBB4B | P68371 | 11/20 | 0.46 |
| ▸ | TUBB3 | Q13509 | 11/20 | 0.46 |
| ▸ | TUBB2A | Q13885 | 11/20 | 0.46 |
| ▸ | TUBB8 | Q3ZCM7 | 11/20 | 0.46 |
| ▸ | TUBA3E | Q6PEY2 | 11/20 | 0.46 |
| ▸ | TUBA1A | Q71U36 | 11/20 | 0.46 |
| ▸ | TUBA1C | Q9BQE3 | 11/20 | 0.46 |
| ▸ | TUBB6 | Q9BUF5 | 11/20 | 0.46 |
| ▸ | TUBB2B | Q9BVA1 | 11/20 | 0.46 |
| ▸ | TUBB1 | Q9H4B7 | 11/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15996366 | 0.94 | CNR2 (0.49) | HSD17B1HSD17B2CNR2TUBB4ATUBB | |
| SCHEMBL724212 | 0.86 | TUBB4A (0.60) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL17732373 | 0.84 | CNR2 (0.56) | HSD17B1HSD17B2CNR2TUBB4ATUBB | |
| SCHEMBL15151686 | 0.81 | TUBB4A (0.53) | HSD17B1HSD17B2CNR2TUBB4ATUBB | |
| SCHEMBL257531 | 0.81 | HPGD (0.54) | CNR2TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL27605120 | 0.79 | HSD17B1 (0.52) | HSD17B1HSD17B2CYP3A4CYP2C9 | |
| SCHEMBL10367856 | 0.76 | ATM (0.55) | HSD17B1HSD17B2CNR2 | |
| SCHEMBL2454052 | 0.72 | TSHR (0.53) | HSD17B1HSD17B2TSHR | |
| SCHEMBL18562033 | 0.70 | ALDH1A1 (0.56) | — | |
| SCHEMBL10367391 | 0.70 | MAPT (0.52) | HSD17B1HSD17B2RXFP1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170226086-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTx. Inc. (US) | 2017-08-10 | — | — | US | disclosed |
| US-9447049-B2 | Compounds for treatment of cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2016-09-20 | — | — | US | disclosed |
| US-8822513-B2 | Compounds for treatment of cancer | GTX, INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-20130197049-A1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2013-08-01 | — | — | US | disclosed |
| US-20120071524-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071524-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | HSD17B1 1191/4885HSD17B2 1371/4885CNR2 3922/4885 |
| US-20130197049-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | HSD17B1 1191/4885HSD17B2 1371/4885CNR2 3922/4885 |
| US-20170226086-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | HSD17B1 1191/4885HSD17B2 1371/4885CNR2 3922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.